DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
מצבים רפואיים
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Lin Shen, M.D.)Contact: Principal Investigator (Lin Shen, M.D)The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact: Study coordinator (Feng Ye, M.D)Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Contact: Study coordinator (Yanqiao Zhang, M.D)The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Contact: Study coordinator (Yanru Qin, M.D)Hubei Cancer Hospital, Wuhan, Hubei, China
Contact: Study coordinator (Huiting Xu, M.D)Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Study coordinator (Zhenyang Liu, M.D)Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Contact: Study coordinator (Yuan Yuan, M.D)Shandong Cancer Hospital, Jinan, Shandong, China
Contact: Study coordinator (Changzheng Li, M.D)Contact: Principal Investigator (Changzheng Li)The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Contact: Study coordinator (Jing Lv, M.D)Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jun Zhang, M.D)West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Hongfeng Gou, M.D)Yunnan Cancer Hospital, Kunming, Yunnan, China
Contact: Study coordinator (Lin Xie, M.D)
מובילי המחקר
Jianmin Fang, Ph.D
Study Director
RemeGen Co., Ltd.